Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.ONC · Entity 2168 | Director | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-01 · Sale · Disposed 235 · Balance 0 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of restricted share units ("RSUs") previously granted to the Reporting Person. The RSUs shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 24,271 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 24,271 |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share represents 13 Ordinary Shares.
F2: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of restricted share units ("RSUs") previously granted to the Reporting Person. The RSUs shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 20:10 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 235 | $279.13 | $65,595.55 |
DisclosureSEC source: 0000919574-26-003800 · ownership.xml · nonDerivative · entry 2 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of restricted share units ("RSUs") previously granted to the Reporting Person. The RSUs shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:19 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | OtherOrdinary Shares | 29,614 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-25-002711 · ownership.xml · nonDerivative · entry 1 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,326 F1 · kind: Represents a transfer of shares by Qingqing Yi ("Mr. Yi") to certain funds managed by his employer and for whose benefit he was holding the shares. Mr. Yi expressly disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:05 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 22,750 | $0.00 Strike: $18.19 | $0.00 |
DisclosureSEC source: 0000902664-25-002529 · ownership.xml · derivative · entry 2 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,750 Underlying: Ordinary Shares · 22,750 shares Expires 2035-05-20 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each ADS represents 13 ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each ADS represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:05 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 10,985 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-25-002529 · ownership.xml · nonDerivative · entry 1 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,940 F1 · shares: Represents securities underlying restricted share units ("RSUs"). All RSUs will vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:31 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 34,151 | $0.00 Strike: $12.23 | $0.00 |
DisclosureSEC source: 0000902664-24-004124 · ownership.xml · derivative · entry 2 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,151 Underlying: Ordinary Shares · 34,151 shares Expires 2034-06-04 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each ADS represents 13 ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each ADS represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:31 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 16,341 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-24-004124 · ownership.xml · nonDerivative · entry 1 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,955 F1 · shares: Represents securities underlying restricted share units ("RSUs"). All RSUs will vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:30 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 26,975 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0000902664-23-003641 · ownership.xml · derivative · entry 2 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,975 Underlying: Ordinary Shares · 26,975 shares Expires 2033-06-14 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each ADS represents 13 ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each ADS represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:30 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 12,922 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-23-003641 · ownership.xml · nonDerivative · entry 1 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,614 F1 · security: Represents securities underlying RSUs. All RSUs will vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 20:15 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | OtherOrdinary Shares | 7,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-22-004101 · ownership.xml · nonDerivative · entry 1 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,692 F1 · security: Represents a transfer of shares by Qingqing Yi ("Mr. Yi") to certain funds managed by his employer and for whose benefit he was holding the shares. Mr. Yi expressly disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. F1 · kind: Represents a transfer of shares by Qingqing Yi ("Mr. Yi") to certain funds managed by his employer and for whose benefit he was holding the shares. Mr. Yi expressly disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:15 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 34,645 | $0.00 Strike: $11.98 | $0.00 |
DisclosureSEC source: 0000902664-22-003398 · ownership.xml · derivative · entry 2 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,645 Underlying: Ordinary Shares · 34,645 shares Expires 2032-06-21 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each ADS represents 13 ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each ADS represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:15 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 16,692 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-22-003398 · ownership.xml · nonDerivative · entry 1 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,492 F1 · security: Represents securities underlying RSUs. All RSUs will vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 16, 2021 Filed Jun 24, 2021 16:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 17,498 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0000902664-21-003255 · ownership.xml · derivative · entry 2 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,498 Underlying: Ordinary Shares · 17,498 shares Expires 2031-06-15 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each ADS represents 13 ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each ADS represents 13 ordinary shares. F3 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 16, 2021 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested shares are subject to accelerated vesting upon change of control or certain termination events. Read SEC document |
| June 16, 2021 Filed Jun 24, 2021 16:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 7,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-21-003255 · ownership.xml · nonDerivative · entry 1 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:15 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 45,383 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0000902664-20-002459 · ownership.xml · derivative · entry 1 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,383 Underlying: Ordinary Shares · 45,383 shares Expires 2030-06-16 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of the issuer's American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of the issuer's American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F1 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of the issuer's American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F1 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of the issuer's American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 14:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | OtherOrdinary Shares | 9,282 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-19-002801 · ownership.xml · nonDerivative · entry 1 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents a transfer of shares by Qingqing Yi ("Mr. Yi") to certain funds managed by his employer and for whose benefit he was holding the shares. Mr. Yi expressly disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. F2 · shares: The 9,290 restricted share units ("RSUs") previously reported by Mr. Yi on June 8, 2018 were revised to 9,282 RSUs to be divisible by 13, as each of the Issuer's American Depositary Shares represents 13 Ordinary Shares. The Share Options previously reported by Mr. Yi on the same date were revised to 17,433 Share Options for the same reason. Read SEC document |
| June 05, 2019 Filed Jun 11, 2019 12:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 64,610 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0000902664-19-002708 · ownership.xml · derivative · entry 1 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,610 Underlying: Ordinary Shares · 64,610 shares Expires 2029-06-04 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F1 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F1 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 22:42 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 17,442 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0000902664-18-002540 · p18-1312form4.xml · derivative · entry 2 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,442 Underlying: Ordinary Shares · 17,442 shares Expires 2028-06-05 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F2 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F2 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 22:42 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 9,290 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-18-002540 · p18-1312form4.xml · nonDerivative · entry 1 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,290 F1 · security: Represents securities underlying restricted share units ("RSUs"). All securities will vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:05 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 199,992 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0000902664-17-002041 · p17-1045form4.xml · derivative · entry 1 Yi Qingqing · CIK 0001662556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,992 Underlying: Ordinary Shares · 199,992 shares Expires 2027-04-18 F1 · derivative.exercise_price: In ordinary shares. One American Depositary Share represents 13 ordinary shares. F1 · shares: In ordinary shares. One American Depositary Share represents 13 ordinary shares. F2 · derivative.exercise_date: The option shall become exercisable in equal installments on the first, second and third anniversary of the grant date and shall become exercisable in full on the date of the third annual meeting of shareholders following the grant date. All vesting shall cease if the Reporting Person resigns from the Issuer's board of directors or otherwise ceases to serve as a director, unless the Issuer's board of directors determines that the circumstances warrant the continuation of vesting. F1 · derivative.underlying_shares: In ordinary shares. One American Depositary Share represents 13 ordinary shares. F1 · balance_after: In ordinary shares. One American Depositary Share represents 13 ordinary shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.